24 December 2014 - United States-based Eli Lilly and Company has signed a five-year research contract with the University of Surrey, it was reported yesterday.

The agreement has been signed to concentrate on health benefits for people with type 2 diabetes, which affects about 95% of those with the disease. Both firms will concentrate on developing answers to commonly asked clinical questions about the continuum of diabetes care, such as the role and timing of injectable therapy, factors impacting adherence to prescribed medicines and the pattern and rationale of therapy following diagnosis.

Lilly Diabetes medical affairs principal research scientist, Brad Curtis, said, 'Living with diabetes is a long and involved journey for patients and their caregivers. It's important for clinicians to understand each step of that journey so patients might have a better chance to reach optimal outcomes. We are honoured to collaborate with the University of Surrey on this important project.'